The Calcium Thread
There is a single element that appears in at least three separate ME/CFS failure modes. Not as a root cause in each case — the mechanisms are different. But as a recurring character: the thing that goes wrong, in different tissues, for different reasons, producing different symptoms that all trace back to the same ion.
Calcium.
1 Failure mode 1: the muscle that cannot recover
After physical or cognitive exertion, many ME/CFS patients experience a delayed crash — post-exertional malaise — that may not peak until 24 to 48 hours later and can last days or weeks. The mechanism proposed by Wirth and Scheibenbogen (Wirth and Scheibenbogen 2021) follows a specific ionic chain.
Muscle cells require a sodium-potassium pump (the Na⁺/K⁺-ATPase enzyme) to maintain their internal chemistry. In ME/CFS, this pump appears to be underperforming — possibly because the beta-2 adrenergic receptors that activate it are dysfunctional, possibly through autoantibody interference. When the pump fails, sodium accumulates inside the cell.
Elevated intracellular sodium triggers the sodium-calcium exchanger — a transporter that normally exports calcium — to run in reverse. Instead of moving calcium out, it imports it.
The result is calcium overload inside muscle cells. Calcium at high intracellular concentrations is toxic. It floods the mitochondria, impairs energy production, triggers oxidative stress, and in severe cases causes structural damage to muscle fibers — visible under electron microscopy in ME/CFS patients. Sodium imaging — a specialized MRI technique that measures sodium ions directly inside muscle tissue — has confirmed the predicted accumulation: ME/CFS patients show a 30% increase in intracellular muscle sodium after exercise, compared to 17% in controls.
This is one of the leading proposed mechanisms behind post-exertional malaise. Not deconditioning. Not psychology. A specific, measurable, ionic cascade that poisons muscle cells when they are pushed past a threshold.
2 Failure mode 2: the immune cell that cannot fire
Natural killer cells are the immune system’s first-responder killers — the cells that identify and destroy infected or abnormal cells. Their killing mechanism depends on calcium. When a natural killer cell recognizes a target, calcium floods in through a specific channel called TRPM3, triggering the degranulation that delivers the killing payload.
In ME/CFS, TRPM3 is broken.
The Griffith University group (Marshall-Gradisnik et al.) has been documenting this for years. TRPM3 channel activity is significantly reduced in the natural killer cells of ME/CFS patients. Calcium influx is impaired. The cells cannot degranulate properly. Their killing capacity is demonstrably reduced. A large-scale 2025 study confirmed this finding across multiple laboratory sites (Sasso et al. 2026) — making it one of the most consistently observed biological abnormalities in ME/CFS, though independent replication by separate research groups is still needed.
Notably, low-dose naltrexone — a treatment many ME/CFS patients report benefit from — appears to partially restore TRPM3 function in these cells. The 2024 paper by Lohn et al. (Wirth and Lohn 2024) documented this effect and proposed TRPM3 dysfunction as a mechanistic explanation for why low-dose naltrexone produces benefit in this population.
Here the calcium problem is upstream, not downstream. The channel itself is dysfunctional — not because of an energy crisis driving a cascade, but as a primary impairment. The immune cell cannot load calcium. It cannot fire. Pathogens or reactivated viruses that the immune system should be clearing are not cleared.
3 Failure mode 3: the brain that cannot rest
During deep slow-wave sleep, thalamic neurons need to oscillate at low frequency — around 1 Hz, the delta rhythm. This is the state in which the brain’s waste-clearance system (the glymphatic system, which depends on these slow oscillations) can function. When you wake up genuinely restored, this is why.
In some ME/CFS patients, and in the majority of fibromyalgia patients, these slow oscillations are contaminated by alpha activity — the brain’s waking frequency (~10 Hz) intruding into deep sleep. The result: sleep that appears normal in duration but fails to restore.
The mechanism, characterized by Timofeev et al. (Timofeev and Bazhenov 2005), traces back to the thalamic calcium channel. Specifically, a class of voltage-sensitive calcium channels in thalamo-cortical neurons — which open and close at low voltages, generating rhythmic bursts — are responsible for producing the slow oscillatory activity that creates delta waves. When thalamic excitability is abnormally elevated — when the circuit cannot properly quiet down — these channels produce higher-frequency oscillations instead. Alpha intrudes. Deep sleep becomes non-restorative.
The calcium channel involved is different from the TRPM3 channel in immune cells and the sodium-calcium exchanger in muscle. Same element, different molecular machinery, different tissue, different clinical consequence.
4 Three failures, three mechanisms — or one?
At this point the picture looks like this:
| Tissue | Calcium problem | Clinical consequence |
|---|---|---|
| Muscle | Sodium-calcium exchanger reversal → calcium overload (secondary to sodium/energy failure) | Post-exertional malaise, exercise intolerance |
| Immune cells | TRPM3 channel dysfunction (primary) | Impaired pathogen clearance, immune exhaustion |
| Thalamus | Voltage-sensitive calcium channel hyperexcitability | Non-restorative sleep, cognitive impairment |
Are these three independent problems that happen to co-occur because ME/CFS is a multisystem disease? Or are they expressions of a single underlying calcium dysregulation?
The TRPM3 hypothesis offers one candidate for a unifying explanation. TRPM3 is not only expressed in immune cells. It is expressed throughout the central nervous system, including in brain neurons. It plays a role in spontaneous neurotransmitter release, in neuronal calcium homeostasis, and in the excitability of sensory and brain circuits. If TRPM3 dysfunction were systemic rather than restricted to immune cells — affecting neurons as well as natural killer cells — it would alter calcium handling in thalamic circuits, potentially contributing to the oscillation abnormalities seen in sleep studies.
This is not established. TRPM3 dysfunction in ME/CFS has been demonstrated only in immune cells. Whether the same impairment exists in thalamic neurons has never been measured. It is a hypothesis, not a finding.
But it is a falsifiable hypothesis. A single experiment — measuring TRPM3 function in neuronal cell models, or in post-mortem brain tissue from ME/CFS patients, or indirectly through imaging of thalamic calcium dynamics — could answer it.
5 What this means for subtypes
The muscle pathway (sodium-calcium exchanger reversal, sodium overload, energy failure driving calcium toxicity) is most likely a secondary mechanism — calcium dysregulation downstream of metabolic crisis. Patients with severe hypoperfusion, significant cardiovascular involvement, or high physical exertion triggers may express this pathway most strongly.
The TRPM3 pathway may be primary — the channel is broken first, and energy failure, immune dysfunction, and possibly sleep disruption follow as downstream consequences. This would be a distinct subtype: a channelopathy-driven phenotype where the root lesion is at the channel level, not the metabolic level.
These two subtypes would predict different treatment responses. Addressing the sodium-calcium cascade (with Na⁺/K⁺-ATPase stimulators, sodium channel blockers, or mitochondrial support) targets the secondary pathway. Restoring TRPM3 function (LDN being the current candidate) targets the primary one. In a patient where both are active, both may be needed.
The same drug given to the wrong subtype would produce no response — and this may explain a substantial fraction of the clinical trial failures in ME/CFS that have puzzled researchers for decades.
6 The thread
One element, three systems, at least two distinct mechanisms, possibly one root cause.
Calcium is not the only story in ME/CFS. But it may be a thread that, when pulled, connects more of the disease than any other single molecule. The muscle pathway and the immune/sleep pathways use different molecular machinery — the connection between them may be metabolic rather than channelopathic. But the immune problem and the sleep problem may share a common root in TRPM3. The patient who has all three may not have three separate diseases. They may have two calcium problems, not one — and one of those two may be reversible.
That experiment — measuring TRPM3 function in thalamic neurons in ME/CFS — has not been done. When it is, the answer will be important.
Part of an ongoing series on the biology of ME/CFS.